Research ArticleArticle
Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts
Glen S. Hazlewood, Claire Bombardier, Xiuying Li, Mohammad Movahedi, Denis Choquette, Louis Coupal, Vivian P. Bykerk, Orit Schieir, Dianne Mosher, Deborah A. Marshall, Sasha Bernatsky, Nicole Spencer, Dawn P. Richards, Laurie Proulx and Claire E.H. Barber on behalf of OBRI, RHUMADATA, CATCH Investigators, the Rheum4U Team
The Journal of Rheumatology August 2021, jrheum.201688 ; DOI: https://doi.org/10.3899/jrheum.201688
Glen S. Hazlewood
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Claire Bombardier
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Xiuying Li
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Mohammad Movahedi
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Denis Choquette
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Louis Coupal
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Vivian P. Bykerk
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Orit Schieir
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Dianne Mosher
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Deborah A. Marshall
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Sasha Bernatsky
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Nicole Spencer
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Dawn P. Richards
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Laurie Proulx
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
Claire E.H. Barber
This project was funded by an Arthritis Alliance of Canada Legacy Award. GSH is supported by a Canadian Institutes of Health Research (CIHR) New Investigator Award. CEHB has an Arthritis Stars Career Development Award, funded by the CIHR Institute of Musculoskeletal Health and Arthritis STAR-19-0611/CIHR SI2-169745. DAM is supported by the Arthur J.E. Child Chair in Rheumatology and a Canada Research Chair in Health Systems and Services Research (2008–2018). The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Amgen and Pfizer Canada, founding sponsors since January 2007; AbbVie and Hoffmann- LaRoche since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016; Merck Canada since 2017; Sandoz Canada, Biopharmaceuticals since 2019; and Gilead Sciences Canada since 2020. The CATCH study was previously funded by Janssen Biotech in 2011–2016, UCB Canada and BMS Canada in 2011–2018, and Sanofi Genzyme in 2016–2017. OBRI was funded by peer-reviewed grants from CIHR, Ontario Ministry of Health and Long-Term Care, Canadian Arthritis Network, and unrestricted grants from AbbVie, Amgen, Celgene, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. The Rheum4U program is supported by unrestricted educational grants from the following pharmaceutical companies: AbbVie, Amgen, BMS, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Swedish Orphan Biovitrum AB (publ; Sobi), and UCB. RHUMADATA is supported by unrestricted grants from AbbVie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, and Sanofi Canada. G.S. Hazlewood, MD, PhD, Associate Professor of Medicine, D.A. Marshall, PhD, Professor, Arthur J.E. Child Chair in Rheumatology Research, C.E.H. Barber, MD, PhD, Associate Professor of Medicine, Department of Medicine, University of Calgary, Department of Community Health Sciences, University of Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, and Arthritis Research Canada, Vancouver, British Columbia, Canada; C. Bombardier, MD, FRCPC, Professor of Medicine, Department of Medicine University of Toronto, Toronto General Research Institute, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; X. Li, MSc, Ontario Best Practices Research Initiative (OBRI), Toronto, Ontario, Canada; M. Movahedi, MD, PhD, Senior Research Associate, Assistant Professor of Epidemiology (Status Only), OBRI, Toronto, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; D. Choquette, MD, FRCPC, Professor of Medicine, L. Coupal, MSc, Université de Montréal, CHUM, Montreal, and RHUMADATA, Montreal, Quebec, Canada; V.P. Bykerk, MD, FRCPC, Professor of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA; 7O. Schieir, PhD, Canadian Early Arthritis Cohort (CATCH), Toronto, Ontario, Canada; D. Mosher, MD, FRCPC, Associate Dean, Strategic Partnerships and Community Engagement, Professor of Medicine, Department of Medicine, University of Calgary, Calgary, and McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Alberta, Canada; S. Bernatsky, MD, PhD, Department of Medicine, McGill University, Montreal, Quebec, Canada; N. Spencer, MSc, Research Assistant, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; D.P. Richards, PhD, L. Proulx, BCom, Canadian Arthritis Patient Alliance, Canada. DC declares the following potential conflicts of interest: AbbVie Canada, Amgen Canada, Eli Lilly Canada, Merk Canada, Novartis Canada, Pfizer Canada, Sandoz Canada, Sanofi Genzyme Canada. VPB is a consultant for Amgen, BMS, Gilead, Sanofi Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G.S. Hazlewood, 3280 Hospital Drive NW, HMRB Building, Room 451, Calgary, AB T2N 4N1, Canada. Email: gshazlew@ucalgary.ca. Accepted for publication July 16, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts
Glen S. Hazlewood, Claire Bombardier, Xiuying Li, Mohammad Movahedi, Denis Choquette, Louis Coupal, Vivian P. Bykerk, Orit Schieir, Dianne Mosher, Deborah A. Marshall, Sasha Bernatsky, Nicole Spencer, Dawn P. Richards, Laurie Proulx, Claire E.H. Barber
The Journal of Rheumatology Aug 2021, jrheum.201688 ; DOI: 10.3899/jrheum.201688
Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts
Glen S. Hazlewood, Claire Bombardier, Xiuying Li, Mohammad Movahedi, Denis Choquette, Louis Coupal, Vivian P. Bykerk, Orit Schieir, Dianne Mosher, Deborah A. Marshall, Sasha Bernatsky, Nicole Spencer, Dawn P. Richards, Laurie Proulx, Claire E.H. Barber
The Journal of Rheumatology Aug 2021, jrheum.201688 ; DOI: 10.3899/jrheum.201688